Joseph Zouein

Mr. Joseph Zouein

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2021 in Immunotherapy
Verified
Journal Article
Closed access
JZJoseph Zouein
Joseph Zouein
FHFadi Haddad
Fadi Haddad
RERoland Eid
Roland Eid
HKHampig Raphael Kourie
Hampig Raphael Kourie
Lung cancer is the second most common cancer worldwide and the leading cause of death among cancers. The progressive approvals of immunotherapy as first-line treatment options have helped improve c...

3 April 2023 in Immunotherapy
Verified
Journal Article
Closed access
SASasha-Jane Abi-Aad
Sasha-Jane Abi-Aad
JZJoseph Zouein
Joseph Zouein
ACAntoine Chartouni
Antoine Chartouni
NNNabih Naim
Nabih Naim
HKHampig Raphael Kourie
Hampig Raphael Kourie
Immunotherapy has improved the prognosis of many cancers, yet a large number of patients have demonstrated resistance to current immune checkpoint inhibitors. LAG-3 is an immune checkpoint expresse... Plain language summary Immunotherapy has increased survival rates for many cancer types; however, a large number of individuals experience resistance to this therapy and poor outcomes. Among the im... Tweetable abstract Coexpression of PD-1 and LAG-3 in solid or hematological cancers may be responsible for immunotherapy resistance; therefore, dual inhibition of PD-1 and LAG-3 may improve treatme...

4 July 2024 in Targeted Oncology
Verified
Journal Article
Closed access
PDF file
JZJoseph Zouein
Joseph Zouein
EKElias Karam
Elias Karam
JSJohn H. Strickler
John H. Strickler
HKHampig Raphael Kourie
Hampig Raphael Kourie

17 October 2022 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
HKHampig Raphael Kourie
Hampig Raphael Kourie
BSBahaa Succar
Bahaa Succar
ECEliane Chouery
Eliane Chouery
CMCybel Mehawej
Cybel Mehawej
NANizar Ahmadieh
Nizar Ahmadieh
ENElie Nemr
Elie Nemr
Background: Bladder cancer (BC) is the 10th most frequent tumor worldwide. Evidence shows an association between elevated risk of BC and various single nucleotide polymorphisms (SNP). BC incidence was the highest in Lebanon according to Globocan 2018 report, but little is known about the genetic susceptibility of Lebanese people to this disease. We aim to evaluate whether this prominent incidence of BC in Lebanon is attributable to known coding genetic variants. Methods: A case-control study was conducted at Hotel-Dieu de France Hospital, Beirut. A cohort of 51 Lebanese patients with BC were recruited between 2017 and 2020. Whole Exome Sequencing (WES) was performed on peripheral blood samples to detect coding genetic variants in the patients. An in-house database including WES data from 472 Lebanese individuals served as control. Literature review of the genetic predisposition to BC was conducted to establish a database of variants known to influence the risk of BC. In-common SNPs were identified between cases and the aforecited database, and their allelic frequencies was quantified in the former and in controls. Comparative analysis of the allelic frequencies of each in-common SNP was carried out between cases, controls, and the genome aggregation database (gnomAD). Analysis was performed by applying the binomial law and setting the p-value to 10− 10. Results: 484 polymorphisms associated with BC were extracted from the literature review ;151 of which were in-common with the 206 939 variations detected by WES in our cases. Statistically significant differences (p-value < 10− 10) in allelic frequencies was seen in 11 of the 151 in-common SNPs, but none of which corresponds with a higher BC risk. Moreover, rs4986782 variant in the NAT1 gene is not associated with BC in the Lebanese population. `. Conclusion: This is the first next-generation sequencing (NGS)- based study investigating BC risk in a Lebanese cohort of 51 patients. The majority of known exonic variants in the literature were not associated with BC in our patients. Further studies with larger sample sizes are warranted to explore the association of BC in our population with known non-coding genetic variants, and the remainder of WES-generated private Lebanese variants.

14 July 2024 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
HKHampig Raphael Kourie
Hampig Raphael Kourie
JZJoseph Zouein
Joseph Zouein
ZZZiad Zalaquett
Ziad Zalaquett
ACAlain Chebly
Alain Chebly
LNLewis Nasr
Lewis Nasr
JTJulien Taieb
Julien Taieb

19 May 2025 in Journal of Asthma
Verified
Journal Article
Closed access
JZJoseph Zouein
Joseph Zouein
LQLoretta G. Que
Loretta G. Que
JIJennifer L Ingram
Jennifer L Ingram
Asthma patients with comorbid obesity tend to have more severe, difficult-to-control asthma than lean asthma patients. This increase in asthma severity may be due, in part, to obesity-related adipokines, such as leptin, which contribute to airway hyperresponsiveness, sustained subclinical chronic inflammation, and treatment resistance. This narrative literature review aims to elucidate the differences in airway eosinophilia and neutrophilia profiles between asthma patients with and without obesity. A PubMed search of full journal articles published between 1992 and 2024 was performed in April 2024 using the terms "asthma", "tissue eosinophilia" and "obesity" combined with the Boolean operator "AND". Articles detailing airway tissue eosinophilia and neutrophilia in asthma patients or mice were included. Only articles in English were included. To date, several studies have reported increased airway tissue eosinophilia in obese mouse asthma models (four studies) and in asthma patients with obesity (three studies). Airway tissue eosinophilia in asthma patients with obesity is driven by altered and elevated levels of adipokines, pro-inflammatory cytokines, and eosinophil-stimulating chemokines such as eotaxin. Leptin and eotaxin levels are increased in asthma with obesity and contribute to enhanced eosinophil recruitment, migration, adhesion to airway smooth muscles and fibroblasts, and reduced apoptosis. Airway tissue eosinophilia is an important feature of obesity-associated asthma. Airway tissue eosinophilia is mainly driven by obesity-related homeostatic changes. These increased airway tissue eosinophils contribute to a more severe disease.